Screening-Detected Versus Interval Lung Cancer in the Biennial Korean National Lung Cancer Screening Program: Proportion, Characteristics, and Mortality
- PMID: 40914393
- DOI: 10.1016/j.jtho.2025.08.024
Screening-Detected Versus Interval Lung Cancer in the Biennial Korean National Lung Cancer Screening Program: Proportion, Characteristics, and Mortality
Abstract
Introduction: Interval lung cancers (ILCs) are key indicators of lung cancer screening (LCS) performance. However, data on the proportion, characteristics, and mortality of ILCs under biennial screening in Asian populations remain limited.
Methods: We analyzed participants from the baseline biennial Korean national LCS program between 2019 and 2020. Screening-detected lung cancers (SLCs) were defined as those diagnosed within 1 year of a positive screening result. ILCs were defined as cancers diagnosed more than 1 year after a negative screening result but within 2 years or before the next screening. Risk factors for ILC were assessed using multivariable logistic regression among participants with a negative screening result. All-cause mortality was compared between SLCs and ILCs using multivariable Cox regression analysis.
Results: Among 124,595 participants, SLCs and ILCs occurred in 0.56% and 0.17%, respectively. ILCs accounted for 18.5% of all lung cancers within 2 years; 65.4% were in Lung-RADS category 1. Risk factors for ILC included older age (adjusted odds ratio [OR], 1.14; 95% confidence interval [CI]: 1.11-1.17; p < 0.001), greater smoking exposure (adjusted OR, 1.010; 95% CI: 1.004-1.016; p = 0.002), a history of malignancy (adjusted OR, 2.22; 95% CI: 1.41-3.51; p < 0.001), emphysema (adjusted OR, 2.88; 95% CI: 2.15-3.85; p < 0.001), and interstitial lung abnormalities (adjusted OR, 4.16; 95% CI: 2.88-6.01; p < 0.001). ILCs had higher all-cause mortality than SLCs (adjusted hazard ratio, 1.43; 95% CI: 1.13-1.80; p = 0.002).
Conclusions: ILCs are common under biennial LCS, making them potentially suboptimal for Asian heavy smokers.
Keywords: Asian population; Interval lung cancer; Low-dose computed tomography; Lung cancer screening; Screening-detected lung cancer.
Copyright © 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Dr. H. Kim received research grants from Kakao Brain and RadiSen; received an honorarium from AstraZeneca; received consulting fees from RadiSen; and holds stock and stock options in Medical IP and stock in Soombit.ai, where he also serves as a Medical Director, outside of submitted work. Dr. Goo received research grants from Coreline Soft and Taejoon Pharm Co., Ltd., outside of submitted work. The remaining authors declare no conflict of interest.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
